Get started Log in

POLB — Poolbeg Pharma Share News

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapMomentum Trap

Immunomodulator II patent granted in Japan
21/11/2023 07:00
POLB 001 LPS Trial Data to be Presented at IUIS
16/11/2023 07:00
POLB001 Data to be Presented at ASH Annual Meeting
03/11/2023 07:05
Brief: Poolbeg Pharma Says Its Scientific Advisory Board Endorsed Influenza Drug Targets Identified In Its Ai-Led Drug Discovery Programme
26/10/2023 07:35
SAB Endorses Influenza Drug Targets
26/10/2023 07:00
Brief: Poolbeg Partners With Biopharma For Development Of Optimised Oral Drug To Treat Metabolic Condition
17/10/2023 07:40
Brief: Poolbeg Pharma Says Notice Of Allowance For Patent Grant In Japan
20/09/2023 07:45
Immunomodulator I Patent Portfolio Strengthened
20/09/2023 07:00
Brief: Poolbeg Pharma PLC Announces Immunomodulator I Patent Opposition Withdrawal
19/09/2023 07:59
Interim results for the six months to 30 June 2023
13/09/2023 07:00
Board Appointment
24/05/2023 07:00
Annual Report & AGM Notice
12/04/2023 07:00
Results for the year ended 31 December 2022
30/03/2023 07:00
Notification of Major Holdings
10/03/2023 07:00
Notification of Major Holdings
09/03/2023 15:51
Brief: Poolbeg Pharma Says Polb 001 Patent Portfolio Was Granted U.S. Patent
08/03/2023 07:34
POLB 001 patent portfolio strengthened
08/03/2023 07:00
Brief: Poolbeg Pharma Says POLB 001 Treatment Exhibited Marked Reduction In Multiple Markers Of Systemic And Local Inflammation
02/03/2023 08:15
Strategic expansion of POLB 001 into oncology
16/01/2023 07:00
Second Price Monitoring Extn
09/01/2023 09:05